LAB Earnings Date: Nov 3, 2026 (Estimated) — Standard BioTools Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is LAB's next earnings date?
Standard BioTools Inc. (LAB) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.02 on revenue of $18.8M.
How did LAB do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Standard BioTools Inc. posted EPS of -$0.07 versus the -$0.01 estimate, a miss of 133.3%. Revenue was $20.1M against a $20.8M estimate. The stock's 1-day post-earnings move was +2.0%.
How much does LAB stock move after earnings?
LAB beat EPS estimates in 1 of its last 6 reported quarters. Over the last 8 reports the stock moved an average of 8.3% (up or down) in the day after earnings.
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.01 | -0.07 | -133.33% | $20.1M | ❌ Miss | +2.04% | +1.28% | -14.05% |
| 2026-05-05 | Q1 2026 | -0.02 | -0.04 | -100.00% | $21.1M | ❌ Miss | -1.07% | +3.17% | +29.72% |
| 2026-02-24 | Q4 2025 | -0.04 | 0.05 | +225.00% | $23.8M | ✅ Beat | +1.74% | -9.57% | -16.35% |
| 2025-11-04 | Q3 2025 | -0.04 | -0.09 | -125.00% | $19.6M | ❌ Miss | -4.20% | +0.00% | +21.01% |
| 2025-08-11 | Q2 2025 | -0.05 | -0.09 | -80.00% | $42.0M | ❌ Miss | +2.34% | -0.78% | +0.00% |
| 2025-02-26 | Q4 2024 | -0.03 | -0.09 | -200.00% | $46.7M | ❌ Miss | -10.68% | +2.56% | -2.56% |
| 2024-07-31 | Q2 2024 | — | -0.12 | — | $37.2M | — | -36.61% | -29.46% | -7.14% |
| 2024-05-08 | Q1 2024 | — | -0.27 | — | $45.5M | — | +7.59% | +12.95% | +3.57% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $34.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 41.9% | $14.5M | -7.4% | $45.4M | $22.2M | $15.7M | $13.8M |
| Consumables | 27.1% | $9.4M | -10.3% | $35.6M | $14.5M | $10.5M | $8.7M |
| Service and Other Revenue | 16.1% | $5.6M | -8.2% | — | — | $6.1M | $5.8M |
| Instruments | 14.8% | $5.1M | -1.6% | $18.0M | $7.8M | $5.2M | $5.1M |
By region
Q2 FY26 · $20.1M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| EMEA | 42.9% | $8.6M | -5.5% | $23.7M | $12.6M | $9.1M | $7.2M |
| Americas | 38.0% | $7.6M | -12.0% | $45.0M | $19.0M | $8.7M | $7.8M |
| Asia Pacific | 19.1% | $3.8M | -2.8% | $15.1M | $9.2M | $3.9M | $4.5M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.